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Abstract 
 
Patients with cirrhosis are highly susceptible for bacterial infections and their severe 
courses. Infections occur more often in advanced stage of liver disease, impair hepatic 
function, trigger the onset of complications, and are significant factors of mortality as 
well. Gastrointestinal hemorrhage confers a higher risk for infections and infections play 
important role in provoking of variceal bleeding episodes and can also be associated with 
the failure to control bleeding. In the past, the dominant pathogens were Gram-negative 
bacteria, but nowadays participation of Gram-positive strains has been increasing. 
Occurrence of opportunistic bacteria is far from rare. Spreading of resistant organisms 
and appearance of Clostridium difficile associated disease related with higher mortality 
are increasing problem due to the consequence of repeated antibiotic treatment of 
recurring infections, multiple hospitalizations and use of long-term antibiotic 
prophylaxis. In cirrhosis, immunodeﬁciency is multifactorial and progresses with the 
disease severity. Thus bacteria commonly get into the circulation from the infection ports 
causing frequent and prolonged bacteremia. Circulating bacteria colonize and proliferate 
in different organs inducing secondary focal infections. Intestinal tract considered a 
significant portal of entry. Translocation of the gut microflora mainly related to the 
development of spontaneous bacterial peritonitis. It is reasonable to assume that 
spontaneous bacteremia leads to other systemic infections but this is yet to be outlined 
adequately. Identification of infectious episodes are challenging due to the lack of typical 
signs and courses up to fifty percent of the cases. Early recognition and effective 
treatment of infections are essential in decreasing the high mortality. 
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ACLF: acute-on-chronic liver failure 
ARF: acute renal failure 
BT: bacterial translocation 
CIRCI: critical illness related corticosteroid insufficiency 
CRP: C-reactive protein 
CDAD: Clostridium difficile associated diseases 
ESBL: extended-spectrum beta-lactamase 
GNB: Gram-negative bacteria 
GPC: Gram-positive cocci 
HE: hepatic encephalopathy,  
Hp: haptoglobin 
HRS: hepatorenal syndrome 
IE: infective endocarditis 
LBP: lipopolysaccharide-binding protein 
MALDI-TOF MS: Matrix Assisted Laser Desorption Ionization –  
Time of Flight Mass Spectometry 
MBL: mannose-binding lectin 
MRSA: methicillin-resistant Staphylococcus aureus 
NSAID: non-steroidal anti-inflammatory drug 
NOD2: nucleotid-binding oligomerization domain containing 2 
PCT: procalcitonin 
PMN: polymorphonuclear leukocyte/ neutrophil 
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RES: reticuloendothelial system 
SBE: spontaneous bacterial empyema 
SBP: spontaneous bacterial peritonitis 
TLR: toll-like receptor 
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Introduction 
 
Association between cirrhosis and bacterial infections has been investigated intensively 
for a long time. Cirrhosis has been characterized as the commonest acquired 
immunodeﬁciency syndrome worldwide. Patients with cirrhosis are highly susceptible for 
bacterial infections and their severe forms. Moreover, infections aggravate the liver failure: 
impair liver functions and trigger the onset of various complications (coagulopathy, 
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hepatorenal syndrome, hepatic encephalopathy, variceal bleeding) and important causes of 
mortality [1]. Bacterial infections have been observed in 32-34% of the hospitalized cirrhotic 
patients [2]. Independent risk factors for bacterial infections are the advanced disease 
depicted by Child-Pugh stage [3, 4] presence of gastrointestinal hemorrhage [5] and existence 
of severe co-morbidity [6]. Approximately 20% of patients with upper gastrointestinal 
bleeding are already infected at admission, and 50% develop an infection during 
hospitalization [7]. On the other hand, there are convincing data that during infectious 
episodes the risk of variceal bleeding is four times higher and these episodes are often 
associated with the failure to control bleeding, predisposition of early rebleeding and 
increased mortality as well [8]. Accordingly, bacterial infections cannot only be the 
consequence, but also – at least partly - the cause of variceal rupture [9, 10]. Once infection 
develops, it adversely affects the survival. The in-hospital mortality of cirrhotic patients with 
infection is more than twice that of patients without infection. Infection is directly responsible 
for 30-50% of death in cirrhosis [2, 4]. During an on-going infection, the advanced cirrhosis, 
presence of renal failure and the hemodynamic instability are definitely bad prognostic 
factors. 
Among patients with cirrhosis and bacterial infection some have ―mere‖ decompensated 
cirrhosis while others exhibit decompensated cirrhosis associated with newly developed liver 
and/or extra-hepatic organ failure(s). Patients with cirrhosis and ―acute‖ organ failure(s) are at 
high risk of short-term death. These patients are considered to have acute-on-chronic liver 
failure (ACLF) [11]. Recently published CANONIC study [12] provided a robust definition 
and grades of ACLF (grade 1-3). Establishment of ACLF grades is based on the numbers of 
organ failures and associated with increasing risk of short-term death from grade 1 (22%) to 
grade 3 (77%). Bacterial infections are the most common precipitating event of ACLF (33%). 
Among patients with bacterial infection, ACLF is more common in spontaneous bacterial 
peritonitis (SBP) or pneumonia than in those with infections of other sites. 
In cirrhosis, during the last decades, dominant pathogens of bacterial infections were 
Gram-negative bacteria (GNB) of the normal intestinal flora, but recently the participation of 
Gram-positive cocci (GPC) has grown due to the invasive procedures and administration of 
the antibiotic prophylaxis. Nowadays, GNB and GPC account for about 50-50% of the 
infectious episodes [13, 14]. Spread of resistant organisms and the higher prevalence of 
Clostridium difficile associated diseases (CDAD) [15] is an imminent threat and significant 
cause of the mortality, especially in patients with multiple hospitalizations, antibiotic 
treatment for recurring infections or secondary prophylaxis of SBP. Widespread use of 
proton-pump inhibitors is also a risk factor for CDAD development in this patient population. 
Monitoring and early detection of CDAD is all the more important. It‘s worth to note, that 
opportunistic bacteria can also be isolated higher frequency [16]. 
About fifty percent of the infections present atypical clinical appearance [2]. Patients 
often have no fever; white blood cell (WBC) count alone is not informative because due to 
hypersplenia the basal WBC count may usually be lower than normal. Thus a WBC count in 
normal range should be considered as leukocytosis, mainly in otherwise leucopenic patients. 
In severe bacterial infections, nevertheless, the WBC count can reach extremely high level. 
Sometimes hepatic encephalopathy (HE) or hepatorenal syndrome (HRS) is the only sign of 
the infection. In cirrhosis, low blood pressure and elevated heart rate is usual as a result of 
hyperkinetic circulation, which are further modified by administration of non-selective beta-
blockers to vast majority of patients. HE that is also a frequent complication during the 
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infectious episodes elevates the rate of breath. For these reasons, the application of classic 
criteria of sepsis has limitations in cirrhosis further delaying the diagnosis of sepsis [17]. To 
identify an infection in time, physicians should always think of its possible existence and seek 
for that thoroughly. Even in the absence of typical signs of infection, screening is highly 
recommended (C-reactive protein CRP and/or procalcitonin PCT [18], urine sediment, 
ascitic fluid polymorphonuclear PMN count, chest X-ray) in those patients who present a 
sudden impairment of the liver function, diuretic-resistant ascites, deteriorating renal 
function, increasing jaundice or encephalopathy. Further thoughtfulness required to localize 
the infection and to find the causative microbe(s). The occurrence of resistant strains and 
unexpected pathogens calls for regular taking of cultures (ascites, blood, urine, sputum, 
wound discharge, etc.) [19].  
 
 
Compromised Host Defense, Prolonged 
Bacteremia 
 
The liver is a bacterial filter
 
and the sinusoidal Kupffer cells play an important role in the 
elimination of intestinal bacteria and endotoxin translocated from the intestine. Patients with 
cirrhosis have impaired function of the reticuloendothelial system (RES) along with a 
decrease in the number and function of Kupffer cells [20, 21]. Additionally, because of the 
formation of collateral circulation, certain part of the blood-volume by-passes the liver, 
reaching directly the systemic circulation. 
Immunodeﬁciency in cirrhosis is multifactorial deeply affecting both the innate and 
adaptive immunity and associated to the disease severity. PMN are fully activated potentially 
through the sustained exposure to bacterial products such endotoxin leading to an energy 
depleted status of the PMN and therefore inability to function properly (decreased 
chemotaxis, phagocytosis and bactericidal capacity). It is not only PMNs that appear 
defective due to the continuous endotoxin exposure. Monocytes show ―immune paralysis‖ as 
well (decreased Fc mediated clearance of bacteria) [22, 23, 24]. Low opsonic activity and 
decreased complement levels, mainly C3, deteriorate the bacterial recognition and 
bactericidal capacity [25]. Fecal IgA content of cirrhotic patients has been reported to be 
lower as compared to healthy subjects, presumably reflecting the decreased mucosal IgA 
secretion. There is T cell depletion in advanced disease as well [26] Genetic immune defects 
(nucleotid-binding oligomerization domain containing 2 [NOD2] variants [27], toll-like 
receptor [TLR] polymorphisms [28] mannose-binding lectin [MBL]
 
deficiency [29], 
haptoglobin polymorphism [Hp] could further deteriorate the immune defence mechanisms 
and could contribute to the high risk of bacterial infections in cirrhosis. Excessive iron stores, 
which are characteristics for certain types of cirrhosis, may have an adverse effect on 
immunity. Iron overload seems to exert subtle effect on immune system by altering the 
proliferation of T and B-lymphocytes [31, 32]. Furthermore, bacteria utilize the iron of the 
host organism as an important nutrient [33]. 
Secondary to compromised local and systemic host defense mechanisms, during local 
infections or often without it, bacteria can easily get into the circulation practically without 
restraint and cause prolonged bacteraemia. In cirrhosis, the occurrence of bacteraemia is five 
times more often and long lasting as compared to the subjects with maintained immunity [34, 
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35]. Gut is a particularly important portal of entry for the bacteria in patients with cirrhosis 
(chronic bacterial translocation BT). Circulating bacteria can colonize and proliferate in 
different organs inducing SBP or even meningitis, endocarditis, sepsis with high mortality. 
Prompt diagnosis and early treatment of these secondary infections are crucial. It would be 
even more important to prevent them. This could happen through the recognition and 
eradication of primary infections and reduction of intestinal bacterial translocation (―closure 
of infection ports‖). The most common bacterial infections are SBP (25%), urinary tract 
infections (UTI) (20%), pneumonia (15%), and bacteremia (12%) [8]. 
 
 
Infection Ports 
 
Bacterial Translocation (BT) 
 
BT means the passage of not only viable bacteria but also endotoxins and other bacterial 
products, such as bacterial DNA itself from the intestinal lumen to the systemic circulation. It 
is considered a normal physiologic event that occurs in healthy individuals without 
deleterious consequences [36]. Small amounts of endotoxin, and bacteria probably constitute 
a physiologically important boost to the RES, especially to the Kupffer cells. Loss of integrity 
of the gut mucosa – as the consequence of inflammation and circulatory disturbance due to 
the portal hypertension –, altered gut micobiota (small bowel bacterial overgrowth) and 
dysmotility, and also the impairment of host defense mechanisms make possible the invasion 
of bacterial products or bacteria themselves into the systemic circulation in greater amount 
leading to systemic inflammatory reaction or overt bacterial infection. BT can turn into 
pathologic event as well. One third of the patients with advanced cirrhosis have small bowel 
hypomotility, decreased IgA secretion into the intestinal lumen due to dysfunction of the 
Paneth cells, altered gut microflora (a decrease in the number of anaerobes with an increase of 
both the GNB and GPC) [26]. Medically induced hypochlorhydria (administration of H2-
receptor blockers, proton-pump inhibitors) and decreased bile acid secretion also contribute to 
the intestinal bacterial overgrowth in the small bowel [37]. Elevated portal pressure 
deteriorates the mucosal integrity of the intestine including widening of intercellular spaces, 
increasing permeability of tight junctions and developing of the edema [26]. However, in 
experimental animals, it has been revealed that the presence of elevated portal pressure is not 
sufficient for the BT and the process itself fairly associated to the advanced parenchymal 
disease [38, 39]. Likewise, in cirrhotic patients subjected to abdominal surgery, growing of 
enteric organism of mesenteric lymph nodes were found in those with the most severe liver 
disease (stage Child C) [40]. Impairment of intestinal wall integrity comprises one of the most 
important portals of entry for the bacteria. In cirrhosis, GNB of the gut microflora are the 
microbes that often translocate from the gut to the systemic circulation. BT becomes 
clinically significant when bacteremia or SBP develops [41]. However, without these overt 
infectious complications sustained exposures to endotoxin has also significant role in the 
further derangement of the previously altered circulatory state and aggravate the preexisting 
portal hypertension in cirrhosis [42, 43]. BT is mainly acknowledged to be an important 
process in the development of SBP. It is reasonable that BT may also possess a pathogenetic 
role in the development of other infections in cirrhotic patients: spontaneous bacteremia may 
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lead to hematogenous spread and secondary focal infections, yet this remains only a theory 
that has not been outlined, or studied adequately at least, in clinical practice [41]. This 
hypothesis is supported by the fact, that patients with increased serum lipopolysaccharide-
binding protein (LBP) level were four times more likely to have severe bacterial infection 
during follow-up than patients with normal LBP [44]. Increased serum LBP level in the lack 
of overt infection is considered as a BT marker. Our group has recently reported, that the 
presence of IgA type anti-microbial antibodies was independently associated with not only 
SBP but also other clinically significant bacterial infections [6, 45]. Marked increase in the 
proportion of IgA2 type antibodies with the presence of secretory component supports the 
involvement of gut mucosal immune system and sustained exposure to bacterial constituents 
as a trigger of antibody formation and development of clinically significant bacterial 
infections as well in cirrhosis. 
 
 
Dental Foci 
 
Any bacterial foci hidden anywhere over the body, can serve a source for the bacterial 
spreading. Systemic infections or even sepsis can start from these loci in 
immunocompromised state. Though majority of cirrhotic patients have poor dental hygiene 
and untreated dental diseases, dental foci are rarely taken into account. Up to 67% of the 
patients suffer from caries due to their lifestyles [46]. Many of them are smokers. Smoking 
itself increases susceptibility to the accumulation of dental plaques, which are the precursors 
for the development of dental caries and periodontal disease. Many drugs administered to 
cirrhotic patients (i.e., mood modifiers with anticholinergic activity, diuretics, and 
antihypertensive agents) may decrease saliva production, causing oral mucosal dryness and so 
that they enhance the occurrence of dental diseases [47]. Dental foci might be the source of 
systemic infection. These infections often caused by unusual bacteria such as Micrococcus, 
Fusobacterium, Peptostreptococcus belongs to the normal oral microflora [46]. 
 
 
Skin and Soft Tissue Infections 
 
Skin and soft tissue infection often develops in cirrhotic patients with edema or ascites 
especially in those suffering from diabetes mellitus concurrently. Cellulitis is found in 2-11% 
of the cases. GPC, Staphylococci and Streptococci are the most prevalent pathogens, but 
Enterobacteriaceae and anaerob bacteria can also be the causes of these infections [41]. GNB 
(Escherichia E. coli, Klebsiella K. pneumoniae) should also be considered as potential 
etiologic agents. In these latter cases, supposedly, the source of the bacteria is the gut itself. 
As a result of BT, enteric bacteria reach the systemic circulation, cause bacteremia and seed 
the tissues of the extremities [48]. Early recognition is important because the course of the 
disease is usually rapid and fatal. Progression to septic shock is common [49]. Inefficiency of 
empirical antibiotics against GPB or appearance of bullous cellulitis and gas formation highly 
suggest GNB infection. Culture of the bullous fluid may facilitate diagnosis and management. 
Antibiotics that are effective against both GBC and GNB should be preferred 
(amoxicillin/clavulanic acid (3x 1.2 g) or moxifloxacin (1x 0.4 g). Zoonosis (Bergeyella 
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zoohelcum [50], Pasturella multocida [51]) can also cause serious cellulitis even without 
injures caused by animal bite.  
 
 
Airways Infections 
 
Airways are the most common entrance for the bacteria. Infections of upper airways can 
easily spread downward to the lung due to the immunocompromised state. In cirrhosis, 
pneumonia is the third most frequent infection (15%). However, the mortality rate of 
pneumonia is much higher than in any non-cirrhotic population [8]. The defect in early 
bactericidal activity of alveolar lining components (reduced levels of lysosim and 
complement C3) explains the extreme sensibility for Pneumococcus pneumonia and the high 
mortality [52]. 
The pathogen spectrum of community acquired pneumonia is similar to general 
population [53]. The higher occurrence and particularly severe course of Pneumococcus 
infection may be worth considering. Pneumococci produce a virulence factor with cytotoxic 
activity called pneumolysin. Pneumolysin activating the complement system and further 
reduces the complement level of cirrhotic patient and attenuate the opsonophagocytic activity 
[52]. Other prevalent pathogens are Klebsiella pneumoniae, Mycoplasma pneumoniae, 
Chlamydia pneumoniae, and Legionella species. As in other localizations, opportunistic 
infection can occur in the lung.  
Treatment strategy of community-acquired pneumonias in cirrhotic patients does not 
differ from the scheme used either in general population [53] likewise other immunodeficient 
states associated with pneumonia [54]. Nonetheless antibiotics should be administered 
intravenously in all cases and except for fluoroquinolones single-drug administration is 
generally not sufficient [53]. Macrolids (e.g., clarithromycin 2x500 mg, azithromycin 1x250 
mg) + third-generation cephalosporins (ceftriaxone with a single dose of 2 g followed by a 
2x1 g, or cefotaxime 3x2 g) could be adequate. An alternative regimen includes macrolid + 
amoxicillin/clavulanic acid (3x1.2 g).
 
The duration of treatment should be 10 days at least; 
antibiotics can be omitted after concomitant resolution of clinical symptoms and 
normalization of CRP level [53]. Newer generation ―respiratory fluoroquinolones‖ 
(levofloxacin, moxifloxacin) having antibacterial activity against GPC as well, can be 
effectively used in monotherapy for either community-acquired typical or atypical 
pneumonias [8]. They are also suitable for early oral administration, which increases the cost 
effectivity of the treatment. The dose of levofloxacin is 2x0.5 g and moxifloxacin is 1x0.4 g. 
Recently, moxifloxacin is considered the most advanced anti-Pneumococcus drug [55].  
Majority of the nosocomial pneumonias are caused by GNB and Staphylococci species. 
In cirrhosis, certain interventions – e.g., intratracheal intubation, esophageal balloon 
tamponade - and the presence of hepatic encephalopathy significantly increase the risk of 
pneumonia. Identification of the pathogen bacteria is very important. In GNB induced 
pneumonias, the treatment of choice could be the third (ceftazidime 3x2 g) or fourth 
generation cephalosporins (cefepime 2-3x2 g), piperacillin/tazobactam (3x4.5 g), imipenem/ 
cilastatin (3-4x0.5-1 g) or meropenem (3x1 g). In Staphylococcus aureus caused pneumonias 
oxacillin/flucloxacillin (4x 2 g-6x1-2 g), high-dose amoxicillin/clavulanic acid (3x2.4 g), or 
moxifloxacin (1x0.4 g) can be used [56]. When methicillin-resistant Staphylococcus aureus 
(MRSA) infection is suspected, the antibiotic regimen should be supplemented with 
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vancomycin (2x1 g). However, linezolid (2x600 mg) yielded a higher rate of both 
microbiological and clinical success than vancomycin [57]. In case of extended-spectrum 
beta-lactamase (ESBL)-producing strains, the effective treatment is imipenem/ cilastatin 
(4x0.5 g) or meropenem (3x1 g) (cefepime or piperacillin/tazobactam could also be used). 
After ruling out Pseudomonas of the causative agents on the basis of the culture result, 
ertapenem (1 g/day) should be the treatment choice. Against carbapenem-resistant strains, 
colisitin (3x1-3 ME/nap) could be effective [58, 59]. New antibiotic strategies tailored 
according to the local epidemiological patterns are needed for the empirical treatment of 
nosocomial infections in cirrhosis not only in pneumonias but also the other type of infections 
[60]. 
When pulmonary aspiration cannot be ruled out, clindamycin (3x600 mg) should be 
added to the treatment regimen, or indicated antibiotics having antibacterial activity against 
anaerobes as well. Ampicillin/sulbactam (4x 1.5 g), amoxicillin/clavulanic acid (3x1.2 g), 
piperacillin/tazobactam (3x4.5 g) or moxifloxacin could equally be suitable in these cases [55, 
61]. 
Patients with cirrhosis – especially those with alcoholic etiology – are more susceptible to 
acquire tuberculosis due to their impaired cellular immune response. During the disease 
course, higher mortality rate and more frequent side effect to anti-tuberculosis drug are 
expected. Because of the preexisting liver dysfunction, application of multi-drug combination 
regimen warrants strict surveillance [62, 63]. 
 
 
Urinary Tract Infections (UTIs) 
 
UTIs are frequent complications in hospitalized cirrhotic patients (20%), however they 
are often asymptomatic. The occurrences of UTIs were found about 5% among non-
hospitalized patients with advanced diseases and on waiting list for liver transplantation [64] 
UTIs are important and often solely precipitating factors of HE [65] and can be the source of 
bacteremia as well. For these reasons, screening of UTIs is important in cirrhotic patients. 
Risk factors of UTIs are urinary catheters dwelling, female gender and concomitant diabetes 
mellitus. The typical pathogens are GNBs (E. coli, K. pneumonia). Recommended empiric 
antibiotic treatment regimes comprise newer quinolone-derivatives (ciprofloxacin 2x500 mg) 
or the traditional trimethoprim/sulfamethoxazole (2x800/160 mg) in uncomplicated 
infections. This latter antibiotic still has a strong anti-GNB activity and reaches high 
concentrations in the urine. Fosfomycin (3 g single dose) or nitrofurantoin (2x100 mg) is also 
recommended as first-line agent [66]. Other antibiotic regimens, mainly in cases of systemic 
UTI, include intravenous amoxicillin/clavulanic acid (3-4x 1.2 g) or cephalosporins 
(cefotaxime 2x2 g or ceftriaxone 1-2x1 g) [19]. One should always consider the history of 
preceding antibiotic treatment when choose empiric antibiotic therapy. The on-going empiric 
antibiotic treatment should be adjusted according to microbiologic results of urine culture. In 
recurrent UTIs, high resistance rate is expected for the previously used antibiotics. 
Unfortunately ESBL producing strains have emerged as significant pathogens in community-
onset infections [67]. 
Lesser is known about the frequencies and courses of other localized infections. During 
bacteremia with unknown origin, it is highly suggested to check maxillary sinus region or 
look for aviator ear, especially in patients with HE and poor cooperation. Following a 
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minimal cranial trauma, in an alcoholic cirrhotic patient with maxillary sinusitis, an extensive 
arborisation of abscess was developed in the tissues of facial and cranial skin (our non-
published case). 
 
 
Secondary Infections 
 
As a consequence of immunocompromised state of cirrhotic patients pathogens can get 
easily into the bloodstream across primary portal of entry, and cause bacteremia. However, 
the occurrence and duration of bacteremia is five times increased as compared to 
immunocompetent subjects [34, 35], which explain the higher incidence of bacterial 
spreading. 
 
 
Spontaneous Bacterial Peritonitis (SBP) 
 
In the presence of ascites, bacteria often colonize ascitic fluid in the peritoneal cavity and 
cause SBP. The low opsonic activity of the ascites – lower than in serum – serves suitable 
environment for bacterial growing [34]. SBP defined as the infection of ascitic fluid in the 
absence of any intraabdominal, surgically treatable source of infection (e.g., perforation or 
abscess). SBP occurs in 10-30% of hospitalized cirrhotic patients with ascites [67, 68]. The 
prevalence is even higher when severe hepatic insufficiency is present indicated by high 
serum bilirubin concentration (>3.2 mg/dl) and low platelet count (< 98 000/mm
3
) or in the 
presence of gastrointestinal bleeding [69]. The low level of total protein (< 1 g/dL) or high 
concentration of LBP in ascitic fluid – the latter is considered an indirect marker of BT – 
significantly increase the risk of SBP [70]. Severe liver dysfunction results in fairly decreased 
protein synthesis. Concomitantly, low ascitic protein level is associated to the impairment of 
opsonic and antibacterial activity in the peritoneal cavity [34]. Gastrointestinal bleeding is 
accompanied by sustained bacteremia [71].  
The underlying mechanisms of SBP have not been fully revealed. SBP is usually 
monomicrobial (in 92% of the cases) and the most common types of pathogens are the 
constituents of intestinal microflora (Enterobacteriaceae) highly suggesting that BT is the 
principal mechanism in its development. Other facts support this notion as well. 
Pharmacological prevention of BT (e.g., by the reduction of portal pressure) diminishes the 
incidence of SBP [72]. Similarly, intestinal decontamination by oral non-absorbable 
antibiotics reduces the occurrence of SBP [73]. Besides BT, SBP could also be a consequence 
of bacteremia associated to primary infections (airway, skin and soft tissue or UTIs) or 
invasive procedures (e.g., endoscopic interventions) through the colonization of the ascitic 
fluid. In these cases, the pathogens are GPC, primarily Streptococcus species. In nosocomial 
SBP, the proportion of GPC is around 59% [74]. 
The clinical signs and symptoms of SBP are aspecific. In early stage, the infection is 
usually asymptomatic, while during the progression signs of peritonitis appear: fever, 
abdominal pain, and tenderness. In almost half of the cases, SBP presents as deterioration of 
consciousness, while one third of the patients complain of diarrhea or ileus. Hypotension or 
hypothermia could also be present, but in less than 20%. Due to scarcity of typical signs and 
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symptoms, diagnostic paracentesis should be performed in all newly discovered cases of 
ascites, including those with Budd-Chiari syndrome or cardiac insufficiency as well. 
Diagnostic paracentesis should also be performed in any cirrhotic patients with ascites 
admitted to hospital due to sudden deterioration of liver function, HE, gastrointestinal 
bleeding or renal impairment [7]. The diagnosis of SBP is based on ascitic fluid analysis 
obtained by paracentesis. An ascitic fluid PMN count  250 cells/mm
3 
independently of
 
culture result is considered diagnostic for SBP and comprises an indication to initiate an 
empirical antibiotic treatment immediately [75]. Ascitic PMN cell counts can be determined 
either by a traditional haematological method using a light microscope and a manual counting 
chamber or by automated cell counters [76]. Advantages of automated cell counter are that 
they are easily accessible in emergencies and provide results within short time [69]. Use of 
reagent test strips to assess leukocyte esterase activity of activated PMNs for the diagnosis of 
SBP cannot be recommended owing to low sensitivity and an unacceptable high rates of false 
negative results [77]. Determination in ascitic fluid of lactoferrin, an iron-binding protein 
contained by PMNs and released on degranulation, might be suitable for bedside diagnosis of 
SBP, however further studies are needed [78]. Besides establishment of the diagnosis, it is 
also important to identify the pathogens causing the SBP episode. Inoculation of ascitic fluid 
into blood culture bottle at bedside increases the sensitivity, even though the culture results 
are negative in 25-50 % of the samples. Collection of separate and simultaneous blood culture 
also yields an increase in the sensitivity. 30-58% of SBP cases are associated with bacteremia 
[69]. Early and more efficient identification of bacteria and their antimicrobial susceptibility 
in ascitic fluid could result in more timely treatment of SBP. Recently, the application of the 
Matrix Assisted Laser Desorption Ionization – Time of Flight Mass Spectometry (MALDI-
TOF MS) to identify bacteria directly from ascitic fluid or from positive blood culture 
proposed for early identification of the causal agent of the infection. Moreover, MALDI-TOF 
MS allows detecting the mechanism of resistance to different antimicrobial agents rapidly 
[79].  
Secondary peritonitis constitutes the main differential diagnosis of SBP. Its mortality is 
much higher than that of SBP (66% vs. 10%) [80]. Diagnosis of secondary peritonitis is based 
on Runyon‘s criteria [81]. A secondary peritonitis is very likely when at least two of the 
following criteria are present in ascitic fluid: glucose levels <50 mg/dl, protein concentration 
>1.0 g/dL, LDH concentration >normal serum levels. 
In community-acquired SBP, the suggested empiric antibiotics are the third-generation 
cephalosporins, which are proved to be effective in 90% of the cases. Cefotaxime should be 
administered intravenously in dose of 3x2 g/ day at least 5 days. However the length of the 
antibiotic treatment should be adjusted individually according to improvement of clinical 
symptoms, and normalization of CRP and ascitic fluid PMN count. The other therapeutic 
options are cefriaxon (1x2 g) or cefonicid (2x2 g) that should be used for 1-2 weeks [43]. Two 
recent studies confirmed the safety and efficacy of intravenously administered 
amoxicillin/clavulanic acid (3-4x1.2 g) in the treatment of SBP [82, 83]. In uncomplicated 
SBP (absence of the followings: ileus, gastrointestinal bleeding, septic shock, HE with grade 
2-4 or serum creatinin  3 mg/dL) oral, highly bioavailable quinolones (ofloxacin 2x400 mg, 
ciprofloxacin 2x500 mg) have been found as effective as the intravenous third-generation 
cephalosporins [84, 85]. However, quinolons are not recommended in patients receiving 
norfloxacin prophylaxis or in geographic areas with a high prevalence of quinolone-resistant 
bacteria. Resistance to third-generation cephalosporins and quinolons increases continuously. 
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Moreover, Enterococci, which are intrinsically resistant to cephalosporins, should be 
considered as one of the causes of treatment failure. The prognosis of enterococcal SBP is 
poor. Adding vancomycin (iv. 2x1 g) to the baseline therapy is effective due to the low 
incidence of vancomycin-resistant strains [86]. Aminoglycosides are also effective against 
Enterococci, however their administration should be avoided due to their increased 
nephrotoxicity in patients with cirrhosis. Regardless of the severity of hepatic insufficiency 
aminoglycoside administration carries a significant risk for development of renal failure and 
should only be used when no other options are available [87]. 
The response to antibiotic therapy should be assessed by follow-up paracentesis and 
monitoring of PMN count in the ascitic fluid. Reduction of the baseline PMN count lesser 
than 25% after 2 days antibiotic therapy suggest treatment failure and warrant adjustment 
[43].  
In nosocomial SBP, the above-mentioned antibiotic regimens lead to unacceptably low 
rates of resolution due to the increasing incidence of ESBL-producing bacteria and 
multiresistant GPBs such as Enterococcus faecium or MRSA [69]. Largely in patients with 
high risk: previous hospitalization (particularly within 3 months and intensive care treatment) 
and prior antibiotic treatment (within 30 days).  
In these cases antibiotic escalation therapy should be avoided due to it has been found to 
be associated with poor survival [88, 89]. Therefore in patients with cirrhosis who develop 
nosocomial SBP and present with such risk factors, carbapenem should be the first-line 
empirical therapy. This regimen should be de-escalated if microbiological results indicate 
non-resistant easily treatable causative microorganisms [69]. Delay in effective therapy 
significantly increases mortality [90].  
The most dreadful complication of SBP and concurrently the important predictor of 
mortality is the development of acute renal failure (ARF). Repeated large-volume 
paracentesis and intensive diuretic treatment can trigger the onset of ARF so that they should 
be avoided in this case. Likewise, all other drugs that may impair renal function – nephrotoxic 
antibiotics or non-steroidal anti-inflammatory drugs (NSAID) should also be avoided until 
full recovery from SBP [17].  
Fluid resuscitation and albumin replacement can improve prognosis. Intravenous albumin 
administration, 1.5 g/kg on the first day, and 1 g/kg on the third day, were found to be 
associated with decreased incidence of renal failure (33% with cefotaxime+albumin vs. 10% 
with cefotaxime alone) and decreased mortality (29% vs. 10%, respectively) [91]. Patients in 
the study who were most likely to benefit from albumin had serum bilirubin levels above 4 
mg/dL and/ or serum creatinine above 1 mg/dL. This observation was confirmed in a 
subsequent study [92]. Consequently, albumin should be reserved for this subgroup of 
patients with SBP [19]. 
Spontaneous bacterial empyema (SBE) is a complication of cirrhotic patients in which a 
pre-existing pleural effusion becomes infected. The mechanism of its development is 
presumably very similar to SBP. The incidence was found 2.4% in cirrhotic patients and 16% 
in patients with cirrhosis with hydrothorax. Predominant pathogens in SBE are GNB, and E. 
coli is the most frequently isolated sole pathogen, similarly to SBP. Approximately half of the 
patients have concomitant SBP as well [93]. The treatment strategy of SBE is in agreement 
with the regimes used in the management of SBP.  
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Meningitis 
 
Though meningitis is a relatively infrequent complication of bacteremia in cirrhosis, the 
susceptibility rate is ten times higher than in general population and these infectious episodes 
are associated with high mortality rate (more than 50%) [94]. Similarly to other infections in 
cirrhosis, establishment of the diagnosis is difficult. Clinical characteristics and signs are 
rarely typical and cirrhosis itself could display central nervous system symptoms as well. One 
third of the patients have no nuchal rigidity. Headache and vomiting is often absent. Coma is 
more common and caused by meningitis and HE together. In the absence of typical clinical 
signs, one rarely thinks of meningeal involvement but more rather HE episode [95]. Besides 
common pathogens like Neisseria meningitidis and Streptococcus pneumoniae, GNB should 
always be considered, mainly in advanced liver disease. Causative agents follow geographic 
distribution patterns: in Taiwan, for example, Kl. pneumoniae was the most frequent pathogen 
mainly in cases with concomitant diabetes mellitus [96], while in France Listeria 
monocytogenes occurred more often [19]. E. coli and Yersinia enterocolitica was also 
reported to cause meningitis [97]. Prognosis of the disease very depends on the early 
diagnosis and proper antibiotic therapy. Taking both cerebrospinal fluid and blood culture is 
very important. Cirrhotic patients often have low platelet count or some other hemostatic 
impairment, so that indication of lumbar puncture is not easy. Though no studies could 
confirm complications related to the procedure up till now [95]. If atypical clinical signs 
develop, one should consider the possibility of brain abscess. In this case lumbar puncture can 
be dangerous (pons herniation) and brain CT is recommended as a first choice for the 
diagnosis establishment [98]. Empirical treatment of the meningitis in cirrhosis should be 
started with a combination of ampicillin and third generation cephalosporin. This regime 
should be modified according to microbiological results. Administration of steroids in 
meningitis is questionable [99]. Recovery from the meningitis is often long with frequent 
relapses. Sustained antibiotic treatment may decrease the prevalence of relapses. Apart from 
immunodeficiency, high mortality rates are also associated to complications (further 
impairment of liver function or HRS). Sometimes the patient recovers from meningitis but 
dies in liver failure.  
Brain abscess develops as a consequence of hematogenous spreading. The most common 
pathogen is Staphylococcus aureus, especially following trauma or brain surgery. 
Streptococcus, Proteus and Serratia species can also be identified. Treatment should be 
started with vancomycin if the suspected bacterium is Staphylococcus, in other cases the 
suggested empiric therapy is a combination of some beta-lactam antibiotic with 
chloramphenicol or metronidasol until the availability of microbiological result. Surgical 
removal of the abscess is not always possible, and very hazardous considering the severe 
comorbidities. The decision is difficult and should always be individual. Postoperative 
mortality rate was 24%, while it turned out to be 45% if no surgery could be performed [100]. 
 
 
Endocarditis 
 
Infective endocarditis (IE) in cirrhotic patients is rarely reported but is a serious hazard 
for hospitalized cirrhotic patients with a 26-80% mortality rate that much higher than non-
cirrhotic population. The most advanced the liver disease is, the higher the mortality rate is. 
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[101]. Operative mortality during valve replacement was extremely high in patients at stages 
B and C [102].
 
Snyder and coworkers [103]
 
reported a three times higher incidence rate in 
patients with cirrhosis as compared to non-cirrhotic subjects (0.34% vs. 0.1%). Guerro et al. 
found that thirty-one (9.8%) patients among 316 cases of IE had hepatic cirrhosis 
[102]
. Thus, 
cirrhotic patients are apparently more susceptible to the development of IE, although the 
overall risk is still fairly low. Staphylococcus aureus was the most common causative 
microorganism in different studies [101, 102], however, in cirrhosis, β-hemolytic 
Streptococci (S. pyogenes, S. agalactiae) were frequently isolated as well. E. coli and 
Pseudomonas aeruginosa were isolated from nosocomial endocarditis. In another study, 
Enterococcus faecalis was also amongst bacterial organisms [101].
 
In cirrhosis, females are 
more frequently affected and endocarditis typically involves the mitral valve. Risk factors for 
nosocomial endocarditis are dwelling of central venous or urinary catheter, and endoscopic 
interventions during gastrointestinal bleeding or liver biopsy. Endocarditis was also reported 
to associate to pneumonia, SBP or hip replacement surgery [101]. Data shows that 
endocarditis in cirrhosis could also develop without a known valvular heart disease. Only in 
the 62% of the cases had previously known valvular heart disease [104, 105]. 
Selecting the best treatment strategy is troublesome: heart surgery is very hazardous in 
this patient population and associated with high postoperative mortality (60-80% in the first 
month) [103]. Furthermore, the anticoagulant therapy may also be challenging due to the 
common occurrence of concomitant hemostatic impairment. Antibiotic selection is also 
problematic. Due to the probable occurrence of Enterococcus faecalis, the foremost-
recommended empiric antibiotics are beta-lactams with gentamycin. This combination seems 
to be the only effective regimen. This combination is also the suggested initial therapy for 
Staphylococci, GNB and Pseudomonas ssp. Administration of aminoglycosids in cirrhosis is 
especially hazardous due to their nephrotoxic properties [87]. However, the risk of 
nephrotoxicity versus the possible harmful effects of omitting an effective treatment option 
should always be carefully considered individually. After receiving microbiologic result, if 
the pathogen is not Enterococcus faecalis and the patient doesn‘t have artificial valve, 
gentamycin can be stopped or replaced. During aminoglycosid therapy the patient requires 
sufficient fluid resuscitation, and close monitoring of renal function and gentamycin serum 
level. Ampicillin (6x 2 g) or ceftriaxone (3x2 g) could be the choices of beta-lactam 
antibiotics. The dose of gentamycin is 2x1 mg/ bwt. In MRSA endocarditis, the antibiotic 
regimen should be supplemented with vancomycin (2x1 g) [106]. 
 
 
Sepsis 
 
Any severe infection could progress into sepsis accompanied by exaggerated 
inflammatory response and multiple organ failure. Unfortunately, in cirrhotic patients the 
classic signs and symptoms of sepsis can be absent or ambiguous, often mistaken with 
general signs of cirrhosis, thus leading to delay in the diagnosis establishment. Hypothermia 
is characteristic for cirrhosis; therefore, temperatures above 37.8 °C should always be taken 
seriously.
 
For a proper evaluation of the actual WBC count considering the previous baseline 
WBC level is very important. Not only absolute but also relative leukocytosis is important. 
This latter category regards to previously leucopenic patients due to hypersplenism. In these 
cases, normal WBC count should be considered ―leukocytosis‖, relative raise in WBC. 
Complimentary Contributor Copy
Zsuzsanna Vitalis and Maria Papp 76 
Hyperkinetic circulation causes higher pulse rate, and hypotension is also not uncommon 
state in cirrhosis. Encephalopathy itself may cause mental disturbances and elevated 
respiratory rates without sepsis. Similarly, increased prothrombin time and elevated liver 
enzymes can be seen in non-septic cirrhosis. Declining renal function is not surely a sign of 
the multiorgan failure in cirrhosis, because of HRS without sepsis can cause impairment of 
kidney function [107]. Sometimes it is very difficult to spot the difference. High serum level 
of CRP and/or PCT, absolute or relative leukocytosis with ‗left shift‘, together with the 
aforementioned symptoms, and rapidly worsening condition of the patient are highly 
suggestive for sepsis. When in doubt, one should always consider the possibility of a septic 
condition. Prognosis of severe sepsis or septic shock is poor with hospital mortality rate from 
30% to 70% [1, 108]. The treatment of sepsis requires integrated strategy in an intensive care 
unit [109, 110] early diagnosis, antibiotic treatment, fluid resustitation, vasoactive drugs and 
other supportive measures (mechanical ventilation, renal replacement therapy, sedation, 
glucose control protocol and prophylactic strategies) if required.  
Regarding antibiotic treatment, broad-spectrum antibiotics covering all likely pathogens 
should be administered as early as possible, always within the first hour if the diagnosis is 
established. De-escalation to the most appropriate single antibiotic should be done once 
susceptibility profile of the responsible bacteria is known [111]. 
In the last ten years it has just been revealed, that adrenal insufficiency in critically ill 
patients with sepsis is far from rare condition. Annane et al. [112] reported an incidence of 
60% in patients with severe sepsis and septic shock. Pathogenesis of adrenal insufficiency is 
complex and poorly understood. In 2008 a consensus statement [113] proposed the term 
critical illness related corticosteroid insufficiency (CIRCI) instead of relative adrenal 
insufficiency (RAI) and defined it as an inadequate peripheral corticosteroid activity for the 
severity of the patients illness. Despite of these facts the effect of low-dose hydrocortisone 
therapy in septic shock patients remains controversial. Randomized controlled trials and 
meta-analyses still show conflicting results. Furthermore, classic diagnostic tools to assess 
adrenal insufficiency used by endocrinologist are not useful in the critically ill patient 
population. At this moment there is no good diagnostic tool that is sensitive and specific 
enough to guide treatment and better definition of adrenal insufficiency is also warranted 
[114]. According to currently published guideline, a continuous infusion of 200 mg 
hydrocortisone per day should only be started if hemodynamic stability is not restored with 
adequate fluid resuscitation and vasopressor therapy. ACTH stimulation test should not be 
used to identify adult septic shock patient that requires hydrocortisone treatment [115]. 
Adrenal insufficiency was found to be a common cause of hemodynamic instability in 
patients with cirrhosis and concomitant sepsis (52–77%) as well. This condition was 
associated with hypotension, which was refractory to volume administration and vasopressor 
drugs, and leaded to mortality rate 81% vs. 37% in patients without adrenal dysfunction 
[116]. Despite of it the efficacy of stress dose steroids on the outcome of cirrhotic patients 
with septic shock is unclear and gastrointestinal bleedings may develop more frequently. At 
this moment, only date of one small, prospective, randomised controlled trial is available. 
This study showed that hydrocortisone, given until shock resolution, was associated with a 
significant reduction in vasopressor doses and a higher rate of shock reversal, but it did not 
reduce 28-day mortality [117]. Assessment of adrenal function and treatment with stress 
doses of hydrocortisone, therefore, is not recommended for the management of severe sepsis 
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in cirrhotic patients for the present. Larger interventional trials are needed to address this 
issue in critically ill cirrhotic patients [19]. 
 
 
Antibiotic Prophylaxis 
 
Antibiotic prophylaxis comprises two distinct approaches. Short-term prophylaxis aims to 
protect against development of a presumed bacteremia, usually following an invasive 
procedure. It should be administrated right before the intervention or short-term thereafter. In 
contrast, long-term antibiotic prophylaxis is used to protect patients with increased 
susceptibility either temporarily or permanently against pathogens invading through any 
portal of entry. This second type of prophylaxis is rather controversial. In cirrhosis both types 
of prophylaxis may play a certain role.  
 
 
Short-Term Prophylaxis 
 
Recent years saw an increasing awareness of endoscopy-related infectious complications. 
Short (< 30 minutes) asymptomatic bacteremia develops in less than 8% after these 
procedures, which rate seems to be unaffected by biopsy taking [118]. The risk is higher 
when performing sclerotherapy (31%), band ligation (1-25%) or esophageal dilatation (45%) 
[119]. Bacteria from the oral flora usually get into the circulation; the most common pathogen 
is Streptococcus viridans. In cirrhosis, however, the risk of infectious complications due to 
bacteremia is significantly higher. Data shows that short-term administration of antibiotics 
following gastrointestinal bleeding and endoscopic intervention improves survival rates and 
decreases the frequency of complications; thus, it is highly recommended [120]. A daily dose 
of 2x 400 mg norfloxacin for 7 days is suitable for the prevention of infectious complications 
followed by gastrointestinal bleeding. The efficacy of amoxicillin (+ clavulanic acid) or non-
absorbable antibiotics is still under investigation. In advanced liver disease (ascites, severe 
malnutrition, HE or icterus), however, 1x1 g of intravenous ceftriaxon proved to be superior 
to oral norfloxacin [121]. In the case of severe vomiting, intravenous antibiotic treatment is 
the only effective way.  
 
 
Long-Term Prophylaxis  
 
The risk of SBP recurrence within one year is up to 70% [122]. Several studies confirmed 
that prolonged intestinal decontamination with nonabsorbable or poorly absorbed oral 
antibiotics is highly effective in preventing SBP recurrence. The recurrence rate decreased 
from 70% to 20-30%. It is established unequivocally, that secondary prophylaxis is 
recommended after resolution of SBP with the strongest evidence supporting use of 
norfloxacin [7]. Prophylactic treatment with trimethoprim/sulfamethoxazole would be much 
cheaper but the efficacy of this combination is yet to be confirmed. Administration of 400 mg 
norfloxacin daily is suggested until the disappearance of ascites, or until liver transplantation 
or death. A recent meta-analysis of Saab et al. [123]
 
showed further advantages of antibiotic 
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prophylaxis in secondary prevention. An improved short-term survival and reduced overall 
risk of infections beyond SBP were also reported in treated patients when compared with 
untreated control groups. 
The role of antibiotic prophylaxis in the primary prevention is uncertain and has to be 
carefully considered. In early studies [124, 125], long-term primary prophylaxis proved to be 
undeniably beneficial in the prevention of GNB caused SBP in patients with low ascitic fluid 
total protein levels (≤ 1 g/dL), however the incidence of extraperitoneal infections or actuarial 
probability of survival did not improved. Recently, Fernandez et al. [126] aimed to investigate 
the efficacy of norfloxacin in the primary prophylaxis of SBP in a very-high risk group of 
patients (low protein ascitic levels [< 1.5 g/dL] with advanced liver failure [Child-Pugh score 
≥ 9 points with serum bilirubin level ≥ 3 mg/dL] or impaired renal function). In this 
randomized placebo-controlled study, primary prophylaxis with norfloxacin had a great 
impact in the clinical course of patients with advanced cirrhosis reducing the incidence of 
SBP, delaying the development of HRS, and improving survival. The most probable 
explanation for these findings is the decreased BT due to the intestinal decontamination. This 
presumption is supported by the laboratory findings of the study. Norfloxacin administration 
diminished the serum levels of LBP, cytokines and nitric-oxide metabolites. Not only the 
translocation of the bacteria themselves, but also their antigens or products may play a role in 
the circulatory derangement characteristic to cirrhotic patients, which is one of the most 
important factors in the development of HRS. HRS, on the other hand, is among the leading 
causes of mortality.  
The trial of Fernandez et al. was considered to fulfill the highest quality criteria and 
represents a well-defined group of patients. Primary prophylaxis can be justified in patients 
with low ascitic protein level (< 1.5 g/dL) and should be used in the presence of advanced 
liver diseases or renal impairment [69]. Wiest et al. also propose that use of norfloxacin for 
primary prophylaxis should also be considered in unselected patients with low ascitic protein 
level if liver transplantation is a realistic option within a few months. In a short-term, the risk 
for selection of resistant strains is low. 
The long-term use of prophylactic antibiotics in cirrhosis has led a selection of quinolone 
resistant bacteria. In early studies [127, 128] development of quinolone-resistant strains in the 
stool of patients on prophylaxis was not associated with an increased incidence of quinolone-
resistant bacteria. However, subsequent studies reported emergence of UTI and SBP caused 
by GNB resistant to quinolones with continuously increasing prevalence in patients receiving 
this prophylaxis [125, 129, 130].  
It is becoming increasingly important to develop non-antibiotic strategies to decrease BT 
and to reduce the incidence of infection in patients with cirrhosis. These non-antibiotic 
strategies include the use of probiotics, prokinetic agents and supplementation with oral bile 
acids and areas of future research [131]. 
 
 
Conclusion 
 
Infections became a central problem in the management of cirrhosis. They affect the 
course of the disease by impairing liver function, increasing the risk of complications and 
thus the mortality rate. Early detection, prompt an adequate antibiotic treatment is of utmost 
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importance. Diagnosis establishment of bacterial infection in cirrhosis is often challenging 
since signs and symptoms could be a specific, often mistaken with other signs of cirrhosis. 
For the chance of an early detection, one most always think of the possibility of bacterial 
infection. New tools for the diagnosis of bacterial infections are also clearly needed. 
Microbiologic results are vital for the diagnosis due to the recent spreading of uncommon, 
multi-resistant or opportunistic pathogens. Third-generation cephalosporins continue to be the 
gold-standard antibiotic treatment of many of the community-acquired infections. For the 
empirical treatment of nosocomial and possibly health-care associated infections data of local 
antimicrobial resistance surveillance should always be considered. Long-term antibiotic 
prophylaxis can decrease BT and the incidence of infections in cirrhosis, but also carries the 
risk of selecting resistant bacteria and CDAD. Unfortunately no single biomarker exists to 
predict the risk of infection in cirrhosis. However, this information is of outstanding clinical 
value. Further research is needed to identify potential biomarkers for immune dysfunction to 
be able to identify the group of patients who benefit most from antibiotic prophylaxis. In the 
future, effective non-antibiotic prophylactic measures should also be sought intensively to 
minimize the risk for the development of bacterial resistance. 
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